BioOutsource Ltd. has formed a partnership with Glythera Ltd., an emerging company specializing in the development of next generation biotherapeutics through the application of its proprietary linker and stable glycan technologies. The move is intended to boost BioOutsource's position in characterization of antibody-drug conjugates (ADCs).
Dr. David Simpson, chief operating officer at Glythera, commented, “We are delighted to have the opportunity to work with BioOutsource on their ADC characterization, as it is an area where our linker technologies offer significant benefits. This partnership demonstrates recognition of these powerful capabilities and we look forward to working with BioOutsource on this exciting project.”
BioOutsource will be exhibiting at the World ADC Summit, in Frankfurt February 17 to 20, in partnership with Aptuit, Glasgow, and with support from Scottish Development International (SDI).
“We are eagerly anticipating exhibiting at the World ADC Summit in Frankfurt,” said Dr. Daniel Galbraith, BioOutsource's chief scientific officer. “We welcome the opportunity to demonstrate our expertise in ADC characterization.”